RKLB Deadline: Rosen Law Firm Urges Rocket Lab USA, Inc. (NASDAQ: RKLB) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
ELF Deadline: Rosen Law Firm Urges e.l.f. Beauty, Inc. (NYSE: ELF) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
QUBT Deadline: Rosen Law Firm Urges Quantum Computing Inc. (NASDAQ: QUBT) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease
BOSTON & HONG KONG–(BUSINESS WIRE)–#GeneTherapy—Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its... Read more.
EyeMD EMR Healthcare Systems, Inc., a Leading Healthcare Technology Provider for Ophthalmologists, Announces Significant Growth Investment from Performant Capital
CHICAGO–(BUSINESS WIRE)–EyeMD EMR Healthcare Systems, Inc., (“EyeMD EMR” or “the Company”), a leading provider of healthcare technology software... Read more.
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium... Read more.
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab... Read more.
NSSC Investors Have Opportunity to Lead Napco Security Technologies, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Napco... Read more.
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
UGN-301 was tolerated across all dose levels, with no dose-limiting toxicities or adverse events leading to treatment discontinuation UGN-301 formulated in a reverse... Read more.
Diamond Comic Distributors Announces Change in Acquisition Partners
HUNT VALLEY, Md.–(BUSINESS WIRE)–Diamond Comic Distributors (“Diamond” or “the Company”), today announced that it will no longer be moving forward... Read more.